Douglas Plassche - Elite Pharma Executive VP of Operations
| ELTPDelisted Stock | USD 0.04 0 6.75% |
EVP
Mr. Douglas Plassche is an Executive Vice President Operations of the Company. He Prior to joining the Company, from 2009 to 2013, Mr. Plassche served as the Managing Director of the New Jersey Solid Oral Dose Operations of Actavis, overseeing 450 employees and the production of more than 100 products. From 2007 to 2009, Mr. Plassche was the Senior Director of Manufacturing for PAR Pharmaceuticals, overseeing 200 employees and the production of more than 70 products. From 1990 2007, Mr. Plassche was employed by ScheringPlough, progressing steadily through multiple disciplines, locations and technical operations sectors with increasing levels of responsibility since 2013.
| Age | 59 |
| Tenure | 11 years |
| Phone | 201 750 2646 |
| Web | https://www.elitepharma.com |
Elite Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0739 % which means that it generated a profit of $0.0739 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.274 %, meaning that it created $0.274 on every $100 dollars invested by stockholders. Elite Pharma's management efficiency ratios could be used to measure how well Elite Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Elite Pharma currently holds 1.39 M in liabilities with Debt to Equity (D/E) ratio of 0.57, which is about average as compared to similar companies. Elite Pharma has a current ratio of 4.41, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Elite Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Elite Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Elite Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Elite to invest in growth at high rates of return. When we think about Elite Pharma's use of debt, we should always consider it together with cash and equity.
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey. Elite Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 43 people. Elite Pharma [ELTP] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Elite Pharma is listed under Pharmaceutical Products category by Fama And French industry classification. Management Performance
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0739 |
Elite Pharma Leadership Team
Elected by the shareholders, the Elite Pharma's board of directors comprises two types of representatives: Elite Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Elite. The board's role is to monitor Elite Pharma's management team and ensure that shareholders' interests are well served. Elite Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Elite Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Douglas Plassche, Executive VP of Operations | ||
| Sophy Abraham, Head Affairs | ||
| Robert Chen, S CFO | ||
| JD MBA, VP Legal | ||
| Nasrat Hakim, Chairman of The Board, CEO and Pres | ||
| Dianne Will, VP of Investor Relations and Corporate Affairs | ||
| Kirko Kirkov, Chief Officer |
Elite Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Elite Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0739 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 27.92 M | ||||
| Shares Outstanding | 1.01 B | ||||
| Shares Owned By Insiders | 17.53 % | ||||
| Shares Owned By Institutions | 0.06 % | ||||
| Number Of Shares Shorted | 757.07 K | ||||
| Price To Earning | 5.21 X |
Pair Trading with Elite Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Elite Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elite Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Elite OTC Stock
| 0.68 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.63 | HLN | Haleon plc | PairCorr |
| 0.58 | OGI | OrganiGram Holdings Fiscal Year End 17th of December 2024 | PairCorr |
| 0.56 | ACB | Aurora Cannabis | PairCorr |
| 0.54 | WUHN | Wuhan General Gr | PairCorr |
The ability to find closely correlated positions to Elite Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Elite Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Elite Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Elite Pharma to buy it.
The correlation of Elite Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Elite Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Elite Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Elite Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Elite OTC Stock
If you are still planning to invest in Elite Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Elite Pharma's history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |